Correct. All this stuff will take at least 2x longer than
Correct. All this stuff will take at least 2x longer than just the math of ideal dates. It was the same for CD10 and 12. We all knew last patient was dosed then it was way way past 28 days. We had to "lock" the data, blah blah. Plus i'm guessing we have to deal with Brazil issues that we didnt have to deal with for CD10/12.
We will all probably gnash our teeth with the debate about interim analysis too. I mean we are so close to full enrollment we should just keep going to really prove to the world about LL. Well maybe not... NP is an idiot for having 40% interim when we all knew it would fill super fast. NP is a dummy for having such a large trial in a foreign country that would take forever to fill. More taste, less filling.
We will probably send stuff to them in spanish then get ignored until we realize we had to send in Portuguese. Plus the email will get stuck in spam, then somehow put in the archive folder unknowingly. I know i sent it but it isnt anywhere i can find it. I mean how can i blame NP for losing an email when its common practice for me. Maybe LL will prove dementia/alzheimer's applicable, or maybe just enough to help me remember my sunglasses are on my head and i left my wallet in the console.
LH. Everyone knows the real money is in LH and if we had only spent more time and gotten LH P3 going we would be in a better spot than chasing severe and critical. I mean NP should have known that covid cases would drop through the floor in brazil. i mean we all saw it, how could he have been so dumb. If only they had done LH in brazil we would be approved by now.
What is the status of the cancer BTD? We have awesome results! Its a slam dunk. Expect variations of this in the coming weeks.
HIV BLA. I think this is getting left on the table simply for us to have something to discuss when we get bored of covid. I mean if it was all done we'd all be swimming in the proverbial respert scrooge mcduck pond of coins and it wouldnt matter.
I would really like to see a reinvigoration of the GvHD. I mean thats been pretty quiet, with the pause of the study. Could someone volunteer to beat this drum and really make some noise so we can have something else to grouse about?
NASH. I really havent spent a bunch of time on this one and dont really understand what the big fuss its. I'm kind of a fatty, so maybe i have a fatty liver. Hopefully LL is better than a keto diet, because i'm kind of a bread guy.
I'm kinda hoping that LL has indications for general inflammation. Ohms list has a bunch of 'itis's and 'osis's on it. My damn plantar fasciitis could maybe use a shot of LL. Also my son who pitches gets a little tendonitis because he doesnt do his core exercises. Both my son and i could continue to be lazy bums and just get an occasional shot of LL and let me live the way i want.
2
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...
Continue Reading
Business stepping up to bat for justice reform? Yeah, that’s what's shaking over in Washington, D.C. this Constitution Day. We're seeing a gathering of senior business execs, policymakers, and public safety advocates, intent on driving judicial reform in the U.S. Usually, the suits in these rooms talk about profit margins and quarterly results, but this time they're...
Continue Reading
From Beachfront Beginnings to Global Fitness Leader Picture this: It's 1992, and Suzelle Snowden has an audacious idea. Teaching fitness classes at resorts in exchange for accommodations. Fast-forward three decades, and now, her brainchild, Fit Bodies, Inc., isn't just a wellness travel company; it's a behemoth, partnering with Hyatt's premier resorts across Mexico, the...
Continue Reading
Shareholder Investigation Shakes Things Up Like a surprise punch straight outta nowhere, Arlo Technologies, Inc. (NYSE: ARLO) finds itself under the magnifying glass of Levi & Korsinsky, LLP. They're sniffing around for possible breaches of fiduciary duties by ARLO's officers and directors. It’s a jolting call for shareholders, who need to stay sharp and not get caught...
Continue Reading
Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...
Continue Reading
The Future of Education Shaped Today There's a profound shift happening in higher education, and it's not the usual undergrad grind most folks think of. Cate Tolnai, stepping into her role at the University of Phoenix, is in the thick of it. She's set to join the UPCEA Council for Credential Innovation's leadership team, and that isn't some fluff title. Her appointment...
Continue Reading
Hormel Foods Takes the Stage at Barclays When it comes to branded food, few players can command attention quite like Hormel Foods Corporation. They're set to make a splash at the upcoming 2026 Barclays Global Consumer Staples Conference. On September 9, Jeff Ettinger, interim CEO, and John Ghingo, the CEO-elect, will lead a fireside chat at 1:30 p.m. ET. They're not just...
Continue Reading
Choosing Your Slice of Paradise in Hilton Head Picture this—not just a sandy paradise for vacationing, but a hotspot for second-home buyers weighing their options like they're sizing up their next big investment. Enter Hilton Head, S.C., a place where strategic move means scooping up properties that marry lifestyle with fiscal savvy. Sizing Up the Dream: More Than Just...
Continue Reading
Legal Storm Brews for Soleno's Execs When you see Kuehn Law stepping into the ring, you know someone’s ruffling feathers. And this time, the target is Soleno Therapeutics (NASDAQ:SLNO), a name that might ring bells for tech folks dabbling in biotech. They’re under the spotlight because a federal securities lawsuit claims a questionable playbook was in the shuffle....
Continue Reading
High-Caliber Recruits Steer Hycroft's Ambitious Path Hycroft Mining's move to bulk up its board ought to raise eyebrows across the mining landscape. By snagging some of the biggest names in the industry, they're not just shuffling the deck—they're bringing in a whole new game plan. If you're tracking NASDAQ:HYMC, this is news you don't brush off. The New Power Quartet...
Continue Reading
Top 5 Most Recently Viewed Articles
Valens Semiconductor to Announce Q2 2025 Financial Results Valens Semiconductor (NYSE: VLN), a leader in high-performance connectivity solutions, has officially shared news regarding its upcoming financial performance for the second quarter of 2025. The company will release these results ahead of the market opening. Investors and stakeholders can anticipate this...
Continue Reading
Understanding the Mullen Automotive Case Mullen Automotive, Inc. has caught the attention of investors and legal experts alike as significant allegations surface regarding potential violations of securities laws. As the market fluctuates, investors who have faced losses exceeding $75,000 within specific timeframes have been prompted to seek justice and explore their legal...
Continue Reading
Understanding Commercial Auto Insurance Mistakes In the world of business, managing commercial auto insurance is crucial. Sissy LeClair from Blackadar Insurance Agency Inc. sheds light on the frequent mistakes companies make regarding their coverage. This insightful discussion highlights the significance of diligent policy management. Common Missteps Businesses Make One...
Continue Reading
Gold Prices Spike as Resource Development Advances Gold prices have recently surged, maintaining levels above $4,200 per ounce, reflecting a steady interest from investors seeking safe-haven assets. The current market conditions invite exploration and drilling programs aimed at expanding existing mineral resources across various regions. Companies are reporting...
Continue Reading
Proton Pump Inhibitors Market Growth Insights The global market for Proton Pump Inhibitors (PPIs) is witnessing impressive growth, with projections indicating an increase of USD 819.5 million from 2025 to 2029. The annual growth rate is expected to reach approximately 4.7% during this period. Various factors contribute to this upward trajectory, notably the driving force...
Continue Reading